person · Reporting owner

Murdoch Travis

Disclosed activity across 2 companies

Tapewire entity: 25566
SEC CIK: 0001845681

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Braveheart Bio, Inc.BRVE · Entity 4564	Director · CEO and President	August 05, 2026	August 07, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Braveheart Bio, Inc.

Report date August 05, 2026 · Filed August 07, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,940,670	Reported balance After 2026-08-07 transaction · row 1 1 source row Row 1 · 2026-08-07 · Purchase · Acquired 83,333 · Balance 2,940,670
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.80 · Expires 2031-08-04	Direct	550,000	Reported balance After 2026-08-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-08-05 · Grant · Acquired 550,000 · Balance 550,000 F2: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of July 23, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.
Common StockSEC Table I · non-derivative	IndirectBy Murdoch Family Trust	3,338,175	Reported balance Holding disclosure · report date 2026-08-05 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 3,338,175 F1: The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Exchange Act or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy Irrevocable Gift Trust for Alizee	1,027,396	Reported balance Holding disclosure · report date 2026-08-05 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 1,027,396 F1: The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Exchange Act or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy Irrevocable Gift Trust for Siena	1,027,396	Reported balance Holding disclosure · report date 2026-08-05 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 1,027,396 F1: The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Exchange Act or for any other purpose.

F2: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of July 23, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Zymergen Inc.

Report date October 19, 2022 · Filed October 19, 2022

Section 16 reporting ended · disclosed 2022-10-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2022-10-19 transaction · row 1 1 source row Row 1 · 2022-10-19 · Disposition to issuer · Disposed 79,697 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 24, 2022 (the "Merger Agreement"), by and among Ginkgo Bioworks Holdings, Inc. ("Ginkgo"), Pepper Merger Subsidiary Inc. and the Issuer, each share of the Issuer's common stock was cancelled and converted into a right to receive 0.9179 of a share of Class A common stock of Ginkgo (the "Merger Consideration"), together with cash in lieu of any fractional shares of Class A common stock of Ginkgo. Immediately prior to the effective time of the merger (the "Effective Time"), all outstanding Issuer restricted stock units ("RSUs") vested in full pursuant to the terms of the agreements governing such Issuer RSUs. Pursuant to the Merger Agreement, immediately prior to the Effective Time, the Issuer RSUs were cancelled and converted into a right to receive the Merger Consideration in respect of such Issuer RSUs and cash in lieu of any fractional shares of Class A common stock of Ginkgo.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of July 24, 2022 (the "Merger Agreement"), by and among Ginkgo Bioworks Holdings, Inc. ("Ginkgo"), Pepper Merger Subsidiary Inc. and the Issuer, each share of the Issuer's common stock was cancelled and converted into a right to receive 0.9179 of a share of Class A common stock of Ginkgo (the "Merger Consideration"), together with cash in lieu of any fractional shares of Class A common stock of Ginkgo. Immediately prior to the effective time of the merger (the "Effective Time"), all outstanding Issuer restricted stock units ("RSUs") vested in full pursuant to the terms of the agreements governing such Issuer RSUs. Pursuant to the Merger Agreement, immediately prior to the Effective Time, the Issuer RSUs were cancelled and converted into a right to receive the Merger Consideration in respect of such Issuer RSUs and cash in lieu of any fractional shares of Class A common stock of Ginkgo.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 07, 2026 Filed Aug 7, 2026 20:30 UTC	Braveheart Bio, Inc. BRVE · Entity 4564	PurchaseCommon Stock	83,333	$18.00	$1,499,994.00	Disclosure SEC source: 0001470831-26-000798 · wk-form4_1786134649.xml · nonDerivative · entry 1 Murdoch Travis · CIK 0001845681 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,940,670 Read SEC document
August 05, 2026 Filed Aug 7, 2026 20:30 UTC	Braveheart Bio, Inc. BRVE · Entity 4564	GrantStock Option (Right to Buy) · Derivative	550,000	$0.00 Strike: $19.80	$0.00	Disclosure SEC source: 0001470831-26-000798 · wk-form4_1786134649.xml · derivative · entry 5 Murdoch Travis · CIK 0001845681 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Stock · 550,000 shares Expires 2031-08-04 F2 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of July 23, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document
October 19, 2022 Filed Oct 19, 2022 23:48 UTC	Zymergen Inc. ZY · Entity 122955	Disposition to issuerCommon Stock	79,697	Not disclosed	Not disclosed	Disclosure SEC source: 0001645842-22-000142 · wf-form4_166622328541897.xml · nonDerivative · entry 1 Murdoch Travis · CIK 0001845681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 24, 2022 (the "Merger Agreement"), by and among Ginkgo Bioworks Holdings, Inc. ("Ginkgo"), Pepper Merger Subsidiary Inc. and the Issuer, each share of the Issuer's common stock was cancelled and converted into a right to receive 0.9179 of a share of Class A common stock of Ginkgo (the "Merger Consideration"), together with cash in lieu of any fractional shares of Class A common stock of Ginkgo. Immediately prior to the effective time of the merger (the "Effective Time"), all outstanding Issuer restricted stock units ("RSUs") vested in full pursuant to the terms of the agreements governing such Issuer RSUs. Pursuant to the Merger Agreement, immediately prior to the Effective Time, the Issuer RSUs were cancelled and converted into a right to receive the Merger Consideration in respect of such Issuer RSUs and cash in lieu of any fractional shares of Class A common stock of Ginkgo. Read SEC document
June 02, 2022 Filed Jun 6, 2022 23:25 UTC	Zymergen Inc. ZY · Entity 122955	GrantCommon Stock	50,000	$0.00	$0.00	Disclosure SEC source: 0001645842-22-000096 · wf-form4_165455791031868.xml · nonDerivative · entry 1 Murdoch Travis · CIK 0001845681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,697 F1 · shares: Represents restricted stock units that vest in full on the earlier of (a) the first annual anniversary of the date of the grant and (b) immediately prior to the Annual Meeting following the date of grant, subject to Reporting Person's continued service to the Board of Directors through the vesting date. Read SEC document
February 14, 2022 Filed Feb 16, 2022 22:51 UTC	Zymergen Inc. ZY · Entity 122955	GrantCommon Stock	29,697	$0.00	$0.00	Disclosure SEC source: 0001645842-22-000019 · wf-form4_164505189730739.xml · nonDerivative · entry 1 Murdoch Travis · CIK 0001845681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,697 F1 · shares: Restricted stock units vest in full on the earlier of (A) the first anniversary of the date of grant and (B) immediately prior to the Annual Meeting following the date of grant, subject to continued service on the Board through the vesting date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.